.jpg "Analysts")
Analysts have been eager to weigh in on the Healthcare sector with new ratings on ImmunoGen (NASDAQ: IMGN), TrovaGene (NASDAQ: TROV) and Bluebird Bio (NASDAQ: BLUE).
ImmunoGen (NASDAQ: IMGN)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright assigned a Buy rating to ImmunoGen (NASDAQ: IMGN), with a price target of $18. The company’s shares opened today at $10.75.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.9% and a 50.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on ImmunoGen is Moderate Buy and the average price target is $14.80, representing a 37.7% upside.
In a report issued on May 3, Canaccord Genuity also maintained a Buy rating on the stock with a $20 price target.
See today’s analyst top recommended stocks >>
TrovaGene (NASDAQ: TROV)
In a report released today, Jason McCarthy from Maxim Group assigned a Hold rating to TrovaGene (NASDAQ: TROV). The company’s shares opened today at $0.28, close to its 52-week low of $0.24.
McCarthy observed:
“Trovagene announced that the first cohort in the P1b/2 study of PCM-075 + low dose chemo in AML (Acute Myeloid Leukemia) has completed dosing and the safety hurdle cleared as per the Safety Review Committee.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 5.6% and a 45.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
TrovaGene has an analyst consensus of Moderate Buy, with a price target consensus of $1.
Bluebird Bio (NASDAQ: BLUE)
In a report released today, Raju Prasad from William Blair assigned a Buy rating to Bluebird Bio (NASDAQ: BLUE). The company’s shares opened today at $180.95.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 24.1% and a 66.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Audentes Therapeutics, and Spark Therapeutics.
Currently, the analyst consensus on Bluebird Bio is Moderate Buy and the average price target is $213.40, representing a 17.9% upside.
In a report issued on May 2, BTIG also reiterated a Buy rating on the stock with a $250 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
